Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to bictegravir/emtricitabine/tenofovir alafenamide in virally suppressed HIV patients with historical resistance
ChiCTR2200063461Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Nanjing
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV) and acquired immunodeficiency syndrome (AIDS), sponsored by The Second Hospital of Nanjing. Primary endpoints: CD4 lymphocyte count and HIV RNA viral load. Planned start Sep 2022; status: not yet recruiting.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)acquired immunodeficiency syndrome (AIDS)
Beyond the preview
Go deeper on ChiCTR2200063461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200063461.